J&J drug gets money-back guarantee

If money-back guarantees sweep the pharma industry, we'll all have Johnson & Johnson to thank. To get its cancer drug Velcade on the UK's National Health Service formulary, the drug maker promised to rebate the cost for patients who don't improve sufficiently after four cycles of treatment. It's the first guarantee of its kind on the NHS, experts say, and might point the way for other pharma firms looking to demonstrate a favorable cost-benefit ratio.

In J&J's case, the National Institute for Clinical Excellence, which accepts or rejects drugs for the NHS, had concluded that Velcade wasn't worth the $6,000-per-treatment-cycle price tag, because some patients responded poorly. The company pitched the rebate, and NICE tentatively agreed--and because no one has appealed the decision, it probably will go into effect October 24.

- see this report from CNN Money

Read more on: Velcade | J&J 

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.